ABSTRACT
INTRODUCTION
Neurological disorders that develop due to degeneration or loss of neural cells, such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and stroke can be devastating and sometimes life-threatening (Ross and Poirier, 2004; Ilieva et al., 2009 ). Disease models based on converted neural cells (cN, refer collectively to the neural cells differentiated from pluripotent stem cells (PSCs) or converted from somatic cells) have been proved effective to investigate mechanisms of certain neurodevelopmental problems and neurodegenerative diseases, identify candidate pathogenic genes, and screen potential drugs (Marchetto et al., 2010; Brennand et al., 2011; Devine et al., 2011; Dolmetsch and Geschwind, 2011; Grskovic et al., 2011; Han et al., 2011; Kim et al., 2011c; Koch et al., 2011; Nguyen et al., 2011; Pasca et al., 2011; Qiang et al., 2011; Yagi et al., 2011; Israel et al., 2012) . For therapeutic purposes, one of the strategies to treat neurodegenerative disease is to replace degenerative neurons with newly produced ones during the course of disease progression. Prior to advances recently made in cN, various cell types including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and fetal neural stem cells (NSCs) have been proposed as donor cells of the cell replacement therapy to treat these diseases. However, there are major obstacles including ethical controversy, immune rejection, and limited cell source that severely impede their potential clinical applications. Until recently, induced pluripotent stem cells (iPSCs) technology offers an unprecedented opportunity to generate patient-specific neural stem/progenitor cells (NSCs/NPCs) in vitro for transplantation purpose. The converted NSCs/NPCs provide unlimited source of donor cells if can be used for cell replacement therapy, at the same time bypassing both immune rejection issue and ethical concern of employing embryonic tissues (Seifinejad et al., 2010; Barrilleaux and Knoepfler, 2011) . The promise of using iPSC-derived NPCs for therapy was strongly supported by the evidence from animal models whose pathological phenotypes can be successfully rescued by effective delivery and integration of converted NPCs into the animal brains (Kikuchi et al., 2011; Kriks et al., 2011; . More recently, induced neural cells (iNs) derived by direct lineage conversion (also termed as transdifferentiation) provide an alternative way to model neurodegenerative diseases and serve as potential donor cells for autologous replacement therapy (Vierbuchen et al., 2010; Kim et al., 2011b; Qiang et al., 2011; Lujan et al., 2012) . © Higher Education Press and Springer-Verlag Berlin Heidelberg 2012 Below we will focus on in vivo properties of cNs, and discuss their therapeutic potentials to treat neurological disorders.
CN AND PD
PD is one of the most prevalent neurodegenerative disorders and characterized by impaired dopaminergic neurons in substantia nigra (Berke and Hyman, 2000; Huse et al., 2005) . In principle, replacement of lost dopaminergic neurons could ameliorate PD symptoms. This was proved to be true by clinical trials where some PD patients grafted with dopaminergic neuroblasts isolated from human fetal mesencephalic tissue recover, at least partially, from disease symptoms (Lindvall and Björklund, 2011) . The major obstacle lies in the difficulty to obtain human fetal tissue. To improve cell therapy approach used in clinic, PSCs including ESCs and iPSCs could serve as excellent cellular sources to produce dopaminergic neurons (Pawitan, 2011) . hESC-derived midbrain dopamine neurons have been successfully transplanted into PD patients' brains and some favorable results were achieved in cell replacement trials (Bjorklund et al., 2002; Kim et al., 2002; Wernig et al., 2004; Roy et al., 2006; Sanchez-Pernaute et al., 2008; Yang et al., 2008; Kriks et al., 2011 ). Studer and colleagues described the differentiation of hESCs into functional dopaminergic neurons, which could be integrated into receiver tissue to ameliorate PD symptoms in mice, rats and monkeys without forming tumors (Kriks et al., 2011) . The milestone improvement in this new strategy is that hPSCs were stepwise differentiated into substantia nigra neurons through floor plate cell stage. The generated neural cells exhibited similar gene expression profile, electrophysiological properties and the ability to release dopamine as nigral neurons, and survived well after transplantation procedures (Kriks et al., 2011) . However, transplantation with hESC derivatives critically suffers from ethical controversy and practical limitation. In contrast, dopaminergic neurons derived from patient specific iPSCs are ideal cellular sources for personalized replacement therapy. The technique to produce dopaminergic neurons from iPSCs was already established (Deleidi et al., 2011) . Fibroblasts from sporadic PD patients could be reprogrammed and differentiated into dopaminergic neurons similarly as those from healthy individuals (Park et al., 2008; Wernig et al., 2008; Soldner et al., 2009 ). Rhee and colleagues were able to generate dopaminergic neurons from protein factors-based iPSCs . The dopaminergic neurons could be successfully transplanted into brains of disease-bearing rats, which significantly rescued the motor deficits caused by 6-OHDAlesion. Integration and survival of iPSCs-derived midbrain dopaminergic neurons were also observed in the brain of a monkey PD model (Kikuchi et al., 2011) . Therefore, all these results shed light on using iPSCs-derived neural cells for therapeutic materials to treat PD. iNs directly converted from somatic cells recently joined the family for the promise of cell replacement therapy. Four independent groups reported the generation of dopamine (DA) neurons by direct lineage conversion (Caiazzo et al., 2011; Kim et al., 2011a Kim et al., , 2011b Pfisterer et al., 2011; Liu et al., 2012b ). Liu's group robustly converted human fibroblasts to DA neuron-like cells using five factors together including Mash1, Ngn2, Sox2, Nurr1, and Pitx3 (Liu et al., 2012b) . These cells expressed markers of DA neurons, exhibited DA uptake and production as well as DA neuron-specific electrophysiological profiles. When transplanted into the middle of the striatum of 6-OHDA-lesioned rats, the rats exhibited a significant stabilization of their rotational behaviors. Kim and colleagues also ectopically expressed certain defined factors in mouse tail tip fibroblasts to induce Pitx3 + neurons that closely resemble mouse DA neurons. When these induced DA (iDA) neurons were transplanted into the striatum of mice with 6-OHDA lesion, the moving behavior of these mice was significantly improved (Kim et al., 2011b) . Thus, iDA neurons produced from somatic fibroblasts by direct lineage reprogramming hold great promise for cell-based therapy.
CN AND ALS
ALS is a fatal and progressive neurodegenerative disease characterized by gradual loss of motor neurons in the brainstem and spinal cord, leading to loss of muscle control and eventual paralysis (Cleveland and Rothstein, 2001; Boillee et al., 2006) . ALS patients may benefit from combinatory therapies involving cell replacement approaches. ALS-bearing animals have been transplanted with donor cells from different origins including MSCs and NPCs to examine their potential therapeutic effects. These approaches were relatively effective in treating disease-bearing animals as life span and motor neuron survival in the hosts were significantly prolonged (Dimos et al., 2008 
CN AND STROKE
Stroke is one of the most common causes of death in human being and there is no effective treatment available to restore lost neurological function of patients after stroke (Donnan et al., 2008) . In the past years, numerous studies have shown that stem cell-based transplantation is an important therapeutic approach for stroke. In 2010, Chen et al. reported that when rats were directly injected with iPSCs into the damaged area of cortex, the infarct size was significantly decreased and their moving behavior was largely improved in rotarod and grasping tasks . However, Kawai et al. did not find any beneficial effect after iPSC transplantation in mice (Kawai et al., 2010) . The discrepancy could be explained by different differentiation and transplantation protocols employed, or different capabilities between species of receiving exogenous iPSCs and functionally incorporating them into nervous system. Recently, Jensen et al. transplanted NSCs derived from human iPSCs into a stroke model, which rescued the stroke volume and behavioral function (Jensen et al., 2011) . Thus the generation of iPSCs from human somatic cells may still offer promising cellular sources for cell-based therapy (Fujioka et al., 2010) .
CN AND OTHER NEUROLOGICAL DISEASES
cN has also shown great potential to treat various neurological diseases like AD (Qiang et al., 2011) , spinal cord injury (SCI) (Nori et al., 2011) , and other neurodegenerative diseases that are summarized in Table 1 . One of the most important breakthroughs comes from Lanza group who successfully transplanted hESC-derived retinal pigment epithelium cells into the eyes of patients with macular degeneration, which led to improved visual activities (Schwartz et al., 2012) .
CONCLUSION AND FUTURE PROSPECTS
cNs provide an unprecedented opportunity to serve as patient-specific autologous transplantation materials for cell replacement therapy of neuronal lesions and incurable neurodegenerative diseases. Animal studies and clinical trials indicate that cN-based cell therapy is very promising to treat neurological diseases. Challenges remain before these cell materials can be safely introduced into human patients. (Kriks et al., 2011) , the fundamental issue that should be further addressed is whether cNs derived from iPSCs are safe after long-term in vivo integration. Notably, genetic aberrancy introduced into iPSCs during reprogramming will be retained in terminally differentiated neural cells. It is uncertain if these changes will affect cellular functions in patients who receive these cells. To avoid unexpected drawbacks due to genetic abnormalities, genomic intact cNs induced by small molecules or other chemically defined conditions should be preferable for clinical applications (Davis et al., 2011; Rhee et al., 2011) . Compared to cNs derived from iPSCs, the ones directly converted from somatic cells have reduced risk of teratoma and cancer formation due to their postmitotic state. Nevertheless, these cells exhibit very limited proliferative ability and may not provide enough autologous donor cells for transplantation. In this case, conversion of fibroblasts into expandable NSCs may be an ideal strategy (Kim et al., 2011a; Lee et al., 2011) . It is worth to note that long-term propagation of NSCs in vitro could cause genomic instability (Varela et al., 2012) . Another concern of cNs obtained from direct lineage conversion is how to correct pathogenic mutations that cause family neurodegenerative diseases. So far, while various gene editing tools have been successfully used for genetic corrections in patient specific iPSCs (Hockemeyer and Jaenisch, 2010; Kim and Svendsen, 2011; Liu et al., 2011; Pan et al., 2011; Liu et al., 2012a; Zhang et al., 2012) , development of more powerful gene editing tools remains a challenge to manipulate genome of somatic cells and represents a critical step for cNs-based therapy. In summary, recent advances on the successful use of cNs in transplantations are exciting and open a new avenue to treat various neurodegenerative diseases. Experiments on animals of disease models have already demonstrated that cNs-based cell replacement therapies are effective in curing certain neurodegenerative diseases. The translation from animals to patients awaits further trials. Major breakthroughs, like powerful gene-editing tools for somatic cells and new techniques to achieve enough, safe, and functional donor cells, have to be made to reduce any potential risk from engrafted autologous tissues. At the same time to take cautions when come to patients, cNs-based cell therapy represents a new era of regenerative medicine to solve incurable medical problems and may finally lead to the cure of some neurodegenerative disorders in the near future.
